Factors associated with ciprofloxacin- and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department

Int J Infect Dis. 2014 Jun:23:8-13. doi: 10.1016/j.ijid.2013.12.021. Epub 2014 Mar 19.

Abstract

Background: High rates of antimicrobial resistance in Escherichia coli isolated from patients with urinary tract infections have been reported worldwide. The aim of this study was to identify risk factors for resistance to ciprofloxacin (CIP) and cefotaxime (CTX) in E. coli isolated from patients with acute pyelonephritis (APN).

Methods: We prospectively identified women over 18 y of age who visited the emergency department of one of 10 hospitals with APN and whose urine culture grew E. coli. The study was conducted from April 16 to June 10, 2012.

Results: Of the 229 patients identified, 173 (75.5%) had community-associated (CA) infections and 56 (24.5%) had healthcare-associated (HCA) infections. Sixty-seven isolates (29.3%) were resistant to CIP, 45 (19.7%) to CTX, and 29 (12.7%) to both CIP and CTX. Multivariate analyses revealed that hematologic disease, chronic kidney disease, a bed-ridden state, indwelling urinary catheter, antibiotic treatment in the preceding 3 months, and isolation of CIP-resistant E. coli in the urine within the preceding 3 months, were significantly associated with resistance to both CIP and CTX.

Conclusions: Chronic conditions and healthcare-associated factors were related to resistance to both fluoroquinolones and third-generation cephalosporins in women with APN. Continued and vigilant surveillance is necessary to monitor the dissemination of antimicrobial resistance in uropathogens.

Keywords: Acute pyelonephritis; Cefotaxime; Ciprofloxacin; Resistance; UTI; Urinary tract infection.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Cefotaxime / therapeutic use*
  • Ciprofloxacin / therapeutic use*
  • Drug Resistance, Multiple, Bacterial*
  • Emergency Service, Hospital
  • Escherichia coli / drug effects
  • Escherichia coli / isolation & purification*
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / epidemiology*
  • Escherichia coli Infections / microbiology
  • Female
  • Fluoroquinolones / therapeutic use
  • Humans
  • Middle Aged
  • Multivariate Analysis
  • Prospective Studies
  • Pyelonephritis / drug therapy
  • Pyelonephritis / epidemiology*
  • Pyelonephritis / microbiology
  • Republic of Korea / epidemiology

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • Ciprofloxacin
  • Cefotaxime